{
  "status": "PASS",
  "confidence": 0.78,
  "rationale": "An approved SOP establishes a policy framework for setting risk acceptability criteria via Risk Management Plans (RMPs), cites applicable regulations/standards and state of the art, includes guidance for evaluating overall residual risk, and specifies document control/access. While the SOP intentionally does not fix universal thresholds, it clearly defines how criteria must be established per product or product family and what inputs to use.",
  "evidence": [
    "Header: \"Document Number: QAP013.01 Title: RISK MANAGEMENT PROGRAM Effective Date: 26Jun2024\"",
    "Section 1.1 Purpose: \"... in accordance with applicable subclauses of ISO 13485:2016, ISO 14971:2019, and taking into consideration the guidelines provided by ISO/TR 24971:2020.\"",
    "Section 3 References: \"21CFR820.30; ISO 14971: 2019; ISO 12971: 2020; ... ISO 62366: 2005\" and footnotes in Definitions citing \"EN ISO 14971:2019/A11:2021\"",
    "Section 2 Responsibilities (Functional Area Management): \"Defines and documents criteria for risk acceptability in the Risk Management Procedure. This provides a framework that ensures that criteria are based upon applicable national or regional regulations and relevant International Standards and considers available information such as the general acknowledged state of the art and known stakeholder concerns.\"",
    "Section 2 Responsibilities (Quality Assurance): \"Defines and documents criteria for risk acceptability in the Risk Management Plan according to the process established in this SOP.\"",
    "Section 5.2.3.2.2: \"Top management of Product Development, Clinical Development, Regulatory Affairs and Quality Assurance establish acceptable thresholds for residual risk acceptance within this procedure.\"",
    "Section 5.2.5: \"Categories of risk and criteria for risk acceptability, in accordance with this procedure, including criteria for accepting risks when the probability of occurrence of harm cannot be estimated. The risk acceptance criteria are based on the following decisions: 5.2.5.1 The risk presented by the current standard of care; 5.2.5.2 The potential health benefits of using the combination product; 5.2.5.3 The generally acknowledged state of the art defined in recognized consensus standards.\"",
    "Section 5.2.6: \"The evaluation method and criteria for acceptability for the overall residual risk, considering all the impact of all risks together, shall be clearly defined and documented in the risk management plan.\"",
    "Section 5.10 Evaluation of Residual Risk: \"After all risk control measures have been implemented and verified, the Applicant shall evaluate the overall residual risk posed by the combination product ... using the method and the criteria for acceptability of the overall residual risk defined in the risk management plan.\"",
    "Table 5 (Section 5.7.4.8): \"Risk Index\" matrix defining Green/Yellow/Red by severity and overall probability of harm (P).",
    "Table 6 (Section 5.9.4.3): \"Required Action Based on Residual Risk Evaluation\" specifying actions for Red/Yellow/Green risk indices (e.g., benefit-risk analysis, risk disclosure, further controls).",
    "Section 5.2.10: \"The risk management plan may be developed for a specific product or for a family of similar products, as appropriate.\"",
    "Section 5.3.5: \"The contents of the risk management file ... shall be controlled and maintained in the document management system in accordance with QAP001...\"",
    "Section 1.3 Scope: \"This SOP does not define the threshold for acceptable risk (or risk index) since this threshold will change based on the intended use and expected benefit of using the combination product.\""
  ],
  "gaps": [
    "No explicit approval signatures or approver names are visible in the provided extract; approval is inferred from the Effective Date.",
    "The SOP relies on RMPs to define specific risk acceptability thresholds; no example RMPs with embedded criteria were provided.",
    "Reference list contains a likely typo (\"ISO 12971: 2020\" instead of ISO/TR 24971:2020) and cites an older usability standard version (\"ISO 62366: 2005\").",
    "The policy does not enumerate device-family-specific principles; it instructs defining them in the RMP when applicable."
  ],
  "recommendations": [
    "Attach or reference an approved RMP example showing documented risk acceptability criteria and overall residual risk criteria for a specific product or product family.",
    "Include the approval record (signatures/approver IDs) or metadata from the document control system to demonstrate formal approval.",
    "Correct and update references: replace \"ISO 12971: 2020\" with \"ISO/TR 24971:2020\" and consider updating usability references to IEC 62366-1:2015+A1:2020.",
    "Optionally add a short statement clarifying that while thresholds are product-specific, the Green/Yellow/Red schema and Table 6 actions constitute the corporate policy framework for determining acceptability and actions.",
    "For device families that share risks, consider adding a template annex or corporate guidance that specifies baseline acceptance principles to be inherited by family RMPs."
  ]
}